$IJT

What iShares Trust (IJT) Sold: Viasat Leads on Oct. 26

iShares Trust (IJT) reported $148.6M net outflow on Oct. 26, selling $1.8M each of VSAT, PTGX, and RHP. IJT holds 345 stocks, with top sectors being Technology, Industrials, and Healthcare. The fund's top holdings include VSAT, PTGX, and RHP, each at around 1.11%. IJT has a P/E of 19.24, P/B of 3.01, and a YTD return of 16.42%.

Original reporting
Published Oct 28, 2026, 11:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 11:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What iShares Trust (IJT) Sold: Viasat Leads on Oct. 26 — source image
Decision brief

The 30-second read

$IJTBearishLow
01

Why it matters

The actionable signal is primarily flow-driven: IJT had net outflows and trimmed several holdings without any reported buys, which can translate into incremental sell pressure for the named constituents.

02

Market read

Traders can use the reported net outflow and top trims as a short-term positioning input, but the article provides no fundamental catalyst for the underlying companies.

03

What to watch

The article does not show whether outflows reversed on subsequent days, nor does it provide the ETF’s creation/redemption activity or whether other funds simultaneously sold the same names.

Relevance 4/10Novelty 3/10Timing: for Oct. 26 ETF flow day, reported on Oct. 28

Background

The piece is an ETF holdings-trading snapshot for iShares Trust IJT, reporting net outflows and the largest underlying trims for Oct. 26.

Company-level read

Ticker impact

$IJTBearishMedium confidence
Context

The article reports iShares Trust IJT had a $148.6M net outflow on Oct. 26, with all gross trading coming from sales and no new positions.

Expected impact

Likely mild downside bias for IJT exposure as the market digests the reported net outflow and continued position trimming.

Evidence & confidence

The piece provides a concrete daily flow figure and confirms no buys, but it does not indicate why flows occurred or whether they persist.

$VSATBearishLow confidence
Context

IJT’s largest sell on Oct. 26 was Viasat (VSAT), trimmed by $1.8M, with no new position or full exit reported.

Expected impact

Slight downward pressure or reduced bid as IJT reduces exposure, with limited standalone impact expected.

Evidence & confidence

The article gives the trimmed dollar amount but provides no confirmation of broader institutional selling or a fundamental change at VSAT.

$PTGXBearishLow confidence
Context

IJT trimmed Protagonist Therapeutics (PTGX) by $1.8M as one of its largest sells on Oct. 26, with no buys that day.

Expected impact

Likely modest negative bias from incremental ETF selling, without a strong directional signal beyond the flow day.

Evidence & confidence

The action is ETF-driven and small relative to company-level trading; no new PTGX-specific news is included.

$RHPBearishLow confidence
Context

IJT’s largest sells included Ryman Hospitality Properties (RHP), trimmed by $1.8M on Oct. 26 with no new positions.

Expected impact

Slight downside pressure as the market accounts for the reported reduction in ETF holdings.

Evidence & confidence

No fundamental or event-driven information about RHP is provided, only the fund’s trading activity.

$TGTXBearishLow confidence
Context

IJT cut TG Therapeutics (TGTX) by $1.5M on Oct. 26, reported as a trim rather than a full exit.

Expected impact

Mild negative drift possible if similar ETF selling continues, otherwise limited impact.

Evidence & confidence

The article does not show broader selling, and the amount is not described as large relative to typical trading.

$ALKSBearishLow confidence
Context

IJT reduced Alkermes (ALKS) by $1.5M on Oct. 26, with the fund reporting no buys for the day.

Expected impact

Slight negative bias from reduced ETF demand, likely fading unless follow-on outflows occur.

Evidence & confidence

The piece is about ETF activity, not company fundamentals, and provides no persistence signal.

Market effects

Because IJT is an equity small and mid-cap fund, net outflows can marginally pressure small/mid-cap risk appetite, but the article does not identify sector-specific drivers.

US-focused ETF flow may slightly affect US small and mid-cap trading liquidity and sentiment.

Limited, as the catalyst is domestic ETF positioning rather than a global macro or cross-border event.

Counterpoint

Daily ETF trims do not necessarily imply bearish fundamentals; they can reflect rebalancing, tax/flow mechanics, or temporary investor redemption timing.

Key entities

  • iShares Trust

    IJT, an equity US small and mid-cap ETF, reported a $148.6M net outflow on Oct. 26 with all gross trading from sales.

  • Viasat

    VSAT was among IJT’s largest trims, down $1.8M on Oct. 26.

  • Protagonist Therapeutics

    PTGX was trimmed by $1.8M as one of IJT’s largest sells on Oct. 26.

  • Ryman Hospitality Properties

    RHP was trimmed by $1.8M as one of IJT’s largest sells on Oct. 26.

Related articles

$TGTXMedAI 8/10

TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026

TG Therapeutics (TGTX) presented Phase 1 data for azer-cel, an allogeneic CD19-directed CAR T-cell therapy, in progressive multiple sclerosis. 89% of evaluable participants showed stable or improved disability scores at Day 90, with no high-grade toxicities observed. The study included 26 participants, with a median follow-up of 4.9 months.

$TGTXMedAI 8/10

First reported test of engineered immune cells in progressive MS found no severe side effects.

TG Therapeutics reported initial results from a Phase 1 study of azer-cel, an allogeneic CD19-directed CAR T-cell therapy, in progressive MS patients. No severe side effects were observed, and 89% of evaluable patients had stable or improved disability scores. Michael S. Weiss, CEO, highlighted the potential of this off-the-shelf therapy for progressive MS. The study included 26 participants with a median follow-up of 4.9 months.

$VSATMed

Viasat Advances NASA Communications Services Project Demonstration with Successful Launch – IT Business Net

Viasat Inc. (NASDAQ: VSAT) advanced its NASA Communications Services Project (CSP) with the successful launch of the Maxwell spacecraft. The mission, part of a $81M contract, will demonstrate Viasat's multi-band, multi-orbit space relay solutions for LEO connectivity. Testing will occur over five months, supporting NASA's transition from its current satellite fleet. Rocket Lab (NASDAQ: RKLB) built the spacecraft, which includes Viasat's Ka- and L-band terminals.